Glaukos Corp Share Price Today: Live Updates & Key Insights

Glaukos Corp share price today is $100.99, up -1.08%. The stock opened at $104.52 against the previous close of $102.09, with an intraday high of $105.17 and low of $100.19.

Glaukos Corp Share Price Chart

Glaukos Corp

us-stock
To Invest in {{usstockname}}
us-stock

Glaukos Corp Share Price Performance

$100.99 -0.0108(-1.08%) GKOS at 23 Mar 2026 01:19 PM Medical Devices
Lowest Today 100.19
Highest Today 105.17
Today’s Open 104.52
Prev. Close 102.09
52 Week High 130.23
52 Week Low 73.16
Day’s Range: Low 100.19 High 105.17
52-Week Range: Low 73.16 High 130.23
1 day return -
1 Week return +1.93
1 month return -16.16
3 month return -13.67
6 month return +19.19
1 year return -6.26
3 year return +108.21
5 year return +14.85
10 year return -

Glaukos Corp Institutional Holdings

BlackRock Inc 14.90

Vanguard Group Inc 10.37

iShares Core S&P Small-Cap ETF 5.99

PRIMECAP Management Company 5.81

State Street Corp 3.62

Ameriprise Financial Inc 3.27

AllianceBernstein L.P. 2.98

Vanguard Total Stock Mkt Idx Inv 2.97

Vanguard Capital Opportunity Inv 2.92

Millennium Management LLC 2.77

American Funds SMALLCAP World A 2.35

iShares Russell 2000 ETF 2.34

JPMorgan Chase & Co 2.31

Geode Capital Management, LLC 2.27

Holocene Advisors, LP 2.24

Vanguard Small Cap Index 2.13

PRIMECAP Odyssey Aggressive Growth 1.92

William Blair Investment Management, LLC 1.91

Janus Henderson Triton D 1.88

Janus Henderson US SMID Cap Growth 1.88

HHG PLC 1.83

BRAIDWELL LP 1.59

Capital World Investors 1.47

Charles Schwab Investment Management Inc 1.23

Artisan Partners Limited Partnership 1.21

Point72 Asset Management, L.P. 1.19

Vanguard Small Cap Growth Index Inv 1.18

Janus Henderson US Small Cap Growth 1.13

Janus Henderson Venture D 1.13

Northern Trust Corp 1.08

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Amvescap Plc. 1.05

Macquarie Group Ltd 1.03

Columbia Small Cap Growth 0.97

Fidelity Small Cap Index 0.94

State Street SPDR Port S&P 600 Sm CpETF 0.92

Columbia Small Cap Growth Inst 0.84

iShares Russell 2000 Growth ETF 0.80

Nomura Small Cap Core I 0.78

Vanguard Explorer Inv 0.75

Glaukos Corp Market Status

Strong Buy: 9

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 1

Glaukos Corp Fundamentals

Market Cap 5865.38 M

PB Ratio 8.939

PE Ratio 0.0

Enterprise Value 5690.50 M

Total Assets 893.49 M

Volume 1143660

Glaukos Corp Company Financials

Annual Revenue FY25:507442000 507.4M, FY24:383481000 383.5M, FY23:303573000 303.6M, FY22:282862000 282.9M, FY21:294011000 294.0M

Annual Profit FY25:282761000 282.8M, FY24:289454000 289.5M, FY23:229667000 229.7M, FY22:213883000 213.9M, FY21:227384000 227.4M

Annual Net worth FY25:-187691000 -187.7M, FY24:-146372000 -146.4M, FY23:-129342000 -129.3M, FY22:-99195000 -99.2M, FY21:-49593000 -49.6M

Quarterly Revenue Q4/2025:143121000 143.1M, Q3/2025:133537000 133.5M, Q2/2025:124120000 124.1M, Q1/2025:106664000 106.7M, Q3/2024:96670000 96.7M

Quarterly Profit Q4/2025:119950000 120.0M, Q3/2025:104706000 104.7M, Q2/2025:97224000 97.2M, Q1/2025:82348000 82.3M, Q3/2024:74086000 74.1M

Quarterly Net worth Q4/2025:-133657000 -133.7M, Q3/2025:-16231000 -16.2M, Q2/2025:-19657000 -19.7M, Q1/2025:-18146000 -18.1M, Q3/2024:-21409000 -21.4M

About Glaukos Corp & investment objective

Company Information Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Organisation Medical Devices

Employees 1094

Industry Medical Devices

CEO Mr. Thomas William Burns

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Glaukos Corp FAQs

What is the share price of Glaukos Corp today?

The current share price of Glaukos Corp is $100.99.

Can I buy Glaukos Corp shares in India?

Yes, Indian investors can buy Glaukos Corp shares by opening an international trading and demat account with Motilal Oswal.

How to buy Glaukos Corp shares in India?

You can easily invest in Glaukos Corp shares from India by:

Can I buy fractional shares of Glaukos Corp?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Glaukos Corp?

Glaukos Corp has a market cap of $5865.38 M.

In which sector does Glaukos Corp belong?

Glaukos Corp operates in the Medical Devices sector.

What documents are required to invest in Glaukos Corp stocks?

To invest, you typically need:

What is the PE and PB ratio of Glaukos Corp?

The PE ratio of Glaukos Corp is N/A and the PB ratio is 8.94.